OMER News and Press, Omeros Corporation From 01/19/21

-- FDA sets PDUFA date of July 17, 2021 -- Omeros Corporation (Nasdaq: OMER) announced today that the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) has been accepte...

Omeros Corporation (Nasdaq: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 39 th Annual J.P. Morgan Healthcare Conference this week. This conference is being held as a virtual conference this year. The presentation is...

A substantive review of its U.S. biopharmaceutical coverage finds BofA looking to a "return to normal" for the sector in a year expected to be dominated by news about a number of COVID-19 vaccines. Biopharma had a strong year overall - with the Biotech side outperforming the broader market (N...

Omeros is unique. It's different from other clinical-stage biotechs in that it has an FDA-approved drug (Omidria) in the market generating revenue to fund ongoing clinical developments. Now, the Omidria reimbursement overhang is gone after CMS confirmed a separate payment mechanism, w...

Omeros, like so many small biotech firms, had myriad challenges in the surreal year of 2020. However, the company is ending the year on some high notes as it has executed a capital raise, completed a BLA submission and received restoration of pass-through status for Omidria. We up...

Gainers: Enlivex Therapeutics (ENLV) +24%, Cellectar Biosciences (CLRB) +18%, Omeros (OMER) +15%, Trxade Group (MEDS) +13%, AlloVir (ALVR) +10%.Losers: ReWalk Robotics (RWLK) -11%, Precision BioSciences (DTIL) -11%, Merrimack Pharmaceutic...

Phoenix New Media (FENG) +115%.Lizhi (LIZI) +97% on collaboration with Xpeng MotorsEver-Glory International Group (EVK) +85%.Nesco Holdings (NSCO) +51% after announcing acquisition of Custom Truck One Source for $1.475B.Cyanotech Corporation (CYAN) +42%.Waddell & Reed Financial ...

— Separate payment for OMIDRIA retroactively effective as of October 1, 2020 — Omeros Corporation (Nasdaq: OMER) announced today that the Centers for Medicare & Medicaid Services (CMS) confirmed separate payment in ambulatory surgery centers (ASCs) for Omer...

Gainers: [[EVK]] +99.3%. [[WDR]] +47.9%. [[OMER]] +22.1%. [[ZS]] +12.1%. [[CRWD]] +11.8%.Losers: [[SPLK]] -18.8%. [[VERI]] -16.6%. [[GLNG]] -7.7%. [[MSP]] -5.4%. [[MACK]] 4.5%. For further details see: EVK, WDR, SPLK and VERI among after-hours movers

Omeros (OMER) +24.7% post-market after a rule from the Centers for Medicare & Medicaid Services showed the company's Omidria qualifies as a non-opioid pain management drug that functions as a surgical supply.According to Bloomberg, the ruling means Omidria will be excluded from packa...